Vitamin D—let common sense prevail—on the balance of probabilities

Rhein, Helga

doi:10.1007/s40520-021-01939-3

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another condition in which a rapid correction of inadequate vitamin D levels has been advocated is COVID-19. While the available evidence based largely on poor-quality observational studies may show a trend for an association between low serum 25(OH)D levels and COVID-19 related health outcomes, this relationship was not found to be always statistically significant [130][131][132]. Calcifediol supplementation may have a protective effect on COVID-19-related ICU admissions in an observational cohort study [133] and in a pilot randomized clinical study [134] and was also associated with lower in-hospital mortality during the first 30 days [135] as well as a lower mortality in patients achieving serum 25(OH)D levels ≥ 75 nmol/L [136], as compared with those not receiving calcifediol.…”

Section: Metabolic Conditions and Treatment With Calcifediol (25-hydr...mentioning

confidence: 99%

Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group

et al. 2022

View full text Add to dashboard Cite

Vitamin D is a key component for optimal growth and for calcium–phosphate homeostasis. Skin photosynthesis is the main source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D supplementation in certain age groups. In older adults, recommended doses for vitamin D supplementation vary between 200 and 2000 IU/day, to achieve a goal of circulating 25-hydroxyvitamin D (calcifediol) of at least 50 nmol/L. The target level depends on the population being supplemented, the assessed system, and the outcome. Several recent large randomized trials with oral vitamin D regimens varying between 2000 and 100,000 IU/month and mostly conducted in vitamin D-replete and healthy individuals have failed to detect any efficacy of these approaches for the prevention of fracture and falls. Considering the well-recognized major musculoskeletal disorders associated with severe vitamin D deficiency and taking into account a possible biphasic effects of vitamin D on fracture and fall risks, an European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group convened, carefully reviewed, and analyzed the meta-analyses of randomized controlled trials on the effects of vitamin D on fracture risk, falls or osteoarthritis, and came to the conclusion that 1000 IU daily should be recommended in patients at increased risk of vitamin D deficiency. The group also addressed the identification of patients possibly benefitting from a vitamin D loading dose to achieve early 25-hydroxyvitamin D therapeutic level or from calcifediol administration.

show abstract

Section: Metabolic Conditions and Treatment With Calcifediol (25-hydr...mentioning

confidence: 99%

Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We read with interest the letter from Dr Helga Rhein, responding to our rapid evidence review around vitamin D and COVID-19 disease [ 1 ]. Dr Rhein suggests that the “evidence for the benefits of avoiding vitamin D deficiency during the pandemic far outweighs the theoretical risk of overdose” [ 2 ]. Thus, “on the balance of probabilities”, should we routinely supplement the population with higher dose vitamin D than the 400 IU/day suggested in the UK as the (dietary) RNI [ 3 ]?…”

mentioning

confidence: 99%